Use of chymase inhibitors for the prevention and/or treatment of arterio-venous graft failure

Abstract

The present invention discloses a method for treating AV graft failure in a patient in need thereof, said method comprising administering to said patient an effective dose of a formulation capable of inhibiting chymotrypsin To generate, release, or inhibit the formation of neointima, the effective dose of the preparation is the dose that can effectively treat the failure of the AV graft.

Description

Background technique [0001] In the United States, approximately 100,000 arteriovenous (A-V) access procedures are performed each year to provide access for renal dialysis (Stanley et al., J. Vasc. Surg. 1996, 23, 172-181). The most commonly used material for dialysis procedures for prosthetics is polytetrafluoroethylene (PTFE or Gore-Tex), but approximately 60% of these grafts fail each year, usually due to stenosis at the end of the vein (Culp et al., Am. J. Kidney Dis. 1995, 26, 341-346; Churchill et al., J. Am. Soc. Nephrol. 1994, 4, 1809-1813; and Feldman et al., Kidney Int. 1993, 43, 1091-1096 ). Similar damage occurs in PTFE grafts placed in the arterial circulation, also at the extremities of the graft that are susceptible to this damage, but the rate of stenosis is not as rapid as in A-V grafts (Cantelmo et al., J. Cardiovasc. Surg. (Torino) 1989, 30, 910-915). Studies have shown that the stenosis of A-V grafts is related to the proliferation and growth of smooth mu...

AI Technical Summary

Problems solved by technology

Based on the above findings, ACE inhibitors have been used in clinical practice to prevent restenosis after PTCA, but this practice was found to be ineffective (MERCATOR Study Group, Circulation 1992, 86, 100-110 and Faxon, J. Am . Coll. Cardiol. 1995, 25, 362-369)

[0003] Contrary to their performance in animal models, ACE inhibitors fail in clinical practice, making research contradictory